8-K: EDAP TMS Reports Record 2025 HIFU Revenue, Strong 2026 Outlook

EDAP TMS SA announced preliminary record fourth quarter and full-year 2025 HIFU revenue, driven by strong system placements and accelerating procedure growth, alongside positive 2026 revenue guidance.

Summary

• Worldwide HIFU revenue for Q4 2025 is expected to range between $12.9 million and $13.3 million, marking the highest quarterly HIFU revenue in company history.
• Annual 2025 worldwide HIFU revenue is projected to be between $36.7 million and $37.2 million, also a record high for the company.
• HIFU revenue growth for 2025 is estimated at 36% to 38% year-over-year.
• A record 15 Focal One system placements occurred during Q4 2025, contributing to a 69% annual year-over-year growth in Focal One system placements.
• U.S. Focal One HIFU procedures increased approximately 28% year-over-year in Q4 2025.
• For the first time, expected HIFU revenue growth represents more than half of the company's total expected annual revenue.
• Initial 2026 financial guidance projects core HIFU business revenue between $50.0 million and $54.0 million, and combined non-core (Distribution and ESWL) business revenue between $22.0 million and $26.0 million.
• Preliminary unaudited non-core revenue for Q4 2025 is expected to be $7.9 million to $8.3 million, with annual 2025 non-core revenue expected at $32.7 million to $33.1 million.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong preliminary financial and operational results, including record revenues, high growth rates, and positive future guidance. The emphasis on increasing clinical validation, market adoption, and expansion into new indications contributes to a highly positive sentiment.

Positives

• Achieved highest quarterly HIFU revenue in company history, expected between $12.9 million and $13.3 million for Q4 2025.
• Achieved highest annual HIFU revenue in company history, expected between $36.7 million and $37.2 million for full-year 2025.
• Reported strong annual year-over-year HIFU revenue growth of 36% to 38%.
• Recorded a record 15 Focal One system placements in Q4 2025, leading to 69% annual year-over-year growth in placements.
• Experienced significant 28% year-over-year growth in U.S. Focal One HIFU procedures in Q4 2025.
• HIFU revenue is expected to constitute over half of the total annual revenue for the first time, validating the execution strategy.
• Provided robust 2026 HIFU revenue guidance of $50.0 million to $54.0 million, indicating continued strong growth.
• Increasing clinical validation from landmark studies like HIFI and FARP Randomized Controlled Trial is driving broader clinical adoption of focal therapy for prostate cancer.
• Focal One is being recognized by large hospital networks as a strategic and necessary investment for comprehensive prostate cancer management.
• The global pipeline is expanding, customer engagement remains strong, and procedure utilization continues to grow.
• Focal One received CE mark certification for the treatment of posterior deep endometriosis infiltrating the rectum on March 25, 2025.
• Strong hospital and physician reimbursement for HIFU, with APC Level 6 maintained by CMS for 2026 and a 90% increase in reimbursement in 2023.

Risks

• The clinical status and market acceptance of HIFU devices may not meet expectations.
• The continued market potential for the lithotripsy and distribution divisions is subject to change.
• Risks are associated with the current worldwide inflationary environment.
• Uncertain worldwide economic, political, and financial conditions could impact operations.
• Geopolitical instability, climate change, and public health crises (like the COVID-19 pandemic) could affect business operations and demand for devices and services.
• Actual results may differ materially from forward-looking statements due to various factors, including those described in the Company's Annual Report on Form 20-F.

Future Outlook

The company anticipates continued strong growth in 2026, with core HIFU business revenue projected to reach $50.0 million to $54.0 million. This outlook is supported by an expanding global pipeline, strong customer engagement, and growing procedure utilization, driven by increasing clinical validation and recognition of Focal One as a strategic investment in prostate cancer management. The company also sees large market opportunities for expansion into Benign Prostatic Hyperplasia (BPH) and Endometriosis treatments.

Management Comments

• "Our preliminary results reflect a strong finish to 2025 and accelerating demand for Focal One across global markets."
• "System placements reached a quarterly record, and procedure growth in the U.S. continues to scale, which we believe reinforces the strength and durability of our recurring revenue model."
• "For the first time in the Company’s history, the expected growth in HIFU revenue represents more than half of our expected annual revenue, validating our execution strategy."
• "We believe increasing clinical validation, including data from key trials such as the landmark HIFI study and FARP Randomized Controlled Trial, is driving broader clinical adoption of focal therapy for prostate cancer."
• "As a result, more large hospital networks are recognizing Focal One as both a strategic and necessary investment in a comprehensive prostate cancer management program."
• "Entering 2026, our global pipeline is expanding, customer engagement remains strong, and procedure utilization continues to grow. Based on this momentum, we are confident in our ability to deliver continued revenue growth and shareholder value creation in the year ahead."

Industry Context

EDAP TMS operates in the rapidly evolving field of robotic energy-based therapies, specifically targeting prostate cancer with its Focal One HIFU technology. The company is capitalizing on a paradigm shift in prostate cancer treatment towards focal therapy, which offers organ-preserving options with improved quality of life outcomes compared to traditional radical treatments like surgery and radiation. The increasing clinical evidence, favorable reimbursement environment (e.g., maintained APC Level 6 by CMS), and expansion into new indications like BPH and endometriosis position EDAP to capture a larger share of the growing urology and women's health markets. The company's focus on advanced imaging, robotics, and AI aligns with broader MedTech trends.

Comparison to Industry Standards

• Focal One HIFU demonstrates comparable cancer control (90% Salvage Treatment Free Survival) to Radical Prostatectomy (86%) in the HIFI study, while offering superior functional outcomes such as urinary continence and less erectile function impairment.
• The FARP Randomized Controlled Trial showed equivalent oncologic control (93.5% Treatment Failure Free) for Focal Ablation (primarily Focal One) compared to Radical Prostatectomy (91.5%), with superior functional outcomes for focal ablation.
• HIFU shows lower 10-year mortality (9.2%) and cancer-specific mortality (5.4%) compared to External Beam Radiation Therapy (16.7% and 9.2% respectively) for stage II prostate cancer.
• Medicare payment for HIFU (CPT 55880) at $9,671 for hospital outpatient services in 2026 is comparable to Cryo Ablation ($9,671) and significantly higher than Prostate Brachytherapy ($5,478), though lower than Laparoscopic/Robotic Prostatectomy ($10,860).
• Physician payment for HIFU (CPT 55880) at $884 in 2026 is higher than Prostate Brachytherapy ($693), Cryo ($692), and MRI Transurethral Ultrasound Ablation ($530), but lower than Laparoscopic/Robotic Prostatectomy ($1,087).

Stakeholder Impact

• Shareholders: Positive impact due to record financial performance, strong growth, and optimistic future guidance, potentially leading to increased share value.
• Customers (Hospitals and Urology Centers): Benefit from advanced Focal One technology for prostate cancer treatment, with increasing clinical validation and favorable reimbursement.
• Patients: Improved treatment options for prostate cancer with better functional outcomes, and potential future non-invasive options for BPH and endometriosis.
• Employees: Positive outlook for company growth and expansion, potentially leading to job security and opportunities.

Next Steps

• Release of completed 2025 annual financial results in March 2026.
• Continued recruitment for Phase I-II study for Benign Prostatic Hyperplasia (BPH) treatment.
• Follow-up of all patients in the Phase III study for Deep Infiltrating Rectal Endometriosis.

Key Dates

Recommendation

The filing indicates exceptional performance with record HIFU revenue, robust year-over-year growth (36-38%), and strong 2026 guidance. The accelerating adoption of Focal One, driven by compelling clinical evidence and favorable reimbursement, positions EDAP as a leader in a growing market. Expansion into BPH and endometriosis further diversifies future revenue streams. These factors collectively suggest significant upside potential and make it a 'strong buy' for a seasoned investor.

Keywords

HIFU, Focal One, Prostate Cancer, Robotic Energy-Based Therapies, Medical Devices, Urology, Financial Results, Revenue Guidance, System Placements, Procedure Growth, Endometriosis, BPH, SEC Filing